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ABSTRACT
Lung cancer screening has come a long way since the
early studies with chest X-ray. Advancing technology and
progress in the processing of images have enabled low
dose CT to be tried and tested, and evidence suggests
its use can result in a signiﬁcant mortality beneﬁt. There
are several issues that need reﬁning in order to
successfully implement screening in the UK and
elsewhere. Some countries have started patchy
implementation of screening and there is increased
recognition that the appropriate management of
pulmonary nodules is crucial to optimise beneﬁts of
early detection, while reducing harm caused by
inappropriate medical intervention. This review
summarises and differentiates the many recent
guidelines on pulmonary nodule management, discusses
screening activity in other countries and exposes the
present barriers to implementation in the UK.
INTRODUCTION
Individuals diagnosed with lung cancer generally
have a poor prognosis, largely attributable to
delayed diagnosis due to the absence of discriminat-
ing symptoms at the early stages of the disease. In
the UK, it was recently estimated for the period
2010–2012 that the net 5-year survival rate of lung
cancer patients was 12.7%1—a reﬂection on the
67.6% of lung cancers that are diagnosed at stage
III or IV.2 One-year survival ranges from 14% for
patients who present with stage IV disease to 71%
for patients with stage I disease.2 Early detection
has the potential to transform lung cancer out-
comes and the case for screening with low radi-
ation dose CT (LDCT) has recently gained
signiﬁcant momentum. However, there is a need to
ensure cost-effectiveness and minimisation of
harms are considered in the face of a considerable
healthcare burden that has arisen from these LDCT
studies; namely the management of the pulmonary
nodule. In this review, we brieﬂy discuss the pedes-
trian history of lung cancer screening through to
the rapid evolution of the present, and highlight
potential important differences in the management
of the pulmonary nodule between recent
guidelines.
THE HISTORY OF LUNG CANCER SCREENING
Studies in screening for asymptomatic lung cancer
began in the 1950s using photoﬂuorograms. As
early as 1959, it was clear that the lung cancer
detection rate varied depending on whether
medical risk was used to select the population to be
screened.3
Early studies using chest X-ray
Unfortunately, the trials for chest X-ray (CXR)
screening for lung cancer failed spectacularly. Four
large randomised controlled trials in the 1970s–
1980s4–7 failed to detect a signiﬁcant mortality
beneﬁt from CXR screening. Sadly, none of these
studies used a true, null screening control group
and rather compared screening with different
modalities or at different frequencies. The Mayo
clinic and Czechoslovakian studies compared CXR
and sputum cytology at lower and higher frequen-
cies.4 7 Both the John Hopkins and Memorial
Sloan Kettering projects compared CXR with or
without sputum cytology.5 6 Likely due to the trial
designs and the short period of follow-up, no statis-
tically signiﬁcant differences in lung cancer-speciﬁc
mortality were detected. However, an increase in
early detection and a threefold increase in long-
term survival were reported in both arms of the
Memorial and Hopkins studies, when compared
with the National Cancer Institutes’ Surveillance
Epidemiology and End Results for unscreened
cancers data.8 At the time, this was attributed to
lead time bias (ie, the apparent increase in survival
observed due to ‘preponing’ the diagnosis rather
than the prolonging of life). Of particular note
however, was an unequivocal difference in 5-year
survival of early-stage detected cancers between
those who had surgical resection (70%) and those
who did not (10%) due to either refusal or medical
contraindication,9 suggesting a successful early
diagnosis strategy should save lives.
Despite the overall negativity following these
early trials, more robust studies were carried out
including the Prostate, Lung, Colorectal and
Ovarian (PLCO) study which started in 1993.
155 000 smokers and non-smokers aged 55–74
were randomised to have either annual CXR for
4 years or no screening. Disappointingly, the
authors reported no effect on lung cancer diagno-
sis, stage, histology or mortality after 13 years of
follow-up.10 A subanalysis of the efﬁcacy of yearly
CXR screening in those at high risk also demon-
strated no effect on lung cancer incidence or
mortality.
Computed tomography
The Mayo Lung Project, a North American single-
arm, LDCT screening pilot carried out in 1999,
detected pulmonary nodules in 74% and lung
cancer in 4% of those screened. The authors con-
cluded that LDCT could detect early-stage lung
cancers but had no signiﬁcant effect on mortality
when compared with subjects screened by CXR in
the earlier Mayo Clinic Study. They suggested that
LDCT screening had led to overdiagnosis of
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indolent early-stage cancers and that due to the high false posi-
tive rate, the risk of complications and expense incurred in the
work-up of false positive lesions, the evidence to support LDCT
screening was inconclusive.11 12
Therefore, the concept of LDCT screening for lung cancer
was largely rejected until the Early Lung Cancer Action
Project.13 14 This study increased the threshold for nodule posi-
tivity to a diameter of 5mm and consequently only 13% of par-
ticipants had baseline scans positive for pulmonary nodules.
The prevalence lung cancer detection rate was 1.2% of all those
screened and 9.7% of positive baseline scans. The majority
(85%) of detected lung cancers were stage I, and these patients
had an estimated 10-year survival rate of 88%. Only 8% of
biopsies revealed benign lesions. These ﬁndings dramatically
transformed prospects for lung cancer screening and it became
apparent that deriving beneﬁt may be possible, but further evi-
dence from well-powered randomised studies was required.
Furthermore, this study emphasised the importance of optimis-
ing protocols to manage positive screens.
This leads us to the pivotal North American, National Lung
Screening Trial (NLST). This was the ﬁrst well-powered rando-
mised study that compared LDCT screening with CXR in
smokers and former smokers aged 55–74. A 20% and 6.7% rela-
tive reduction in lung cancer-speciﬁc and all-cause mortality,
respectively, was observed across the two groups; with a number
needed to screen of 320 to save one life from lung cancer after
three annual screens and seven years of follow-up.15 The use of
CXR as a control has provoked controversy, as some argue the
lack of mortality beneﬁt observed by screening smokers and
former smokers in the PLCO trial justiﬁes CXR as equivalent to
null screening, while others have argued otherwise.16 Another
limitation of this study is that the majority of NLST participants
were younger, white, well-educated and afﬂuent, while higher
risk individuals were under-represented. This brings us to two
important observations. First, the failure to engage those most at
risk of lung cancer in screening in the NLST study may have led
to an underestimation of the potential beneﬁt of screening. But
second, this study importantly highlights the difﬁculties faced in
undertaking a cost-effective screening approach across society.
NLST radically changed prospects for LDCT screening, but
can these data be extrapolated to the UK and Europe? One of
the aims of the UK Lung Cancer Screening Trial (UKLS) was to
address this and to evaluate costs within the UK National
Health Service (NHS).17 Several other trials in Europe have also
recruited, but those that reported on mortality were substan-
tially underpowered and failed to detect a beneﬁt.18–23
Combining the populations within these studies together with
the Dutch-Belgian lung cancer screening trial (NELSON), the
Danish Lung Cancer Screening Trial and UKLS will amount to a
total of approximately 36 000 participants; although, with
varying nodule management algorithms and criteria for eligibil-
ity. The pooled results are eagerly awaited by physicians and
health providers alike, and should mature in 2016.24
LDCT: MANAGEMENT OF PULMONARY NODULES
The studies discussed have clariﬁed the CT features of nodules
and growth rates that support benign or malignant diagnoses.25–
30 Several predictive models taking into account clinical and
demographic factors, as well as CT and positron emission tom-
ography (PET) features of nodules have been proposed and vali-
dated, enabling quantiﬁcation of risk of malignancy for a given
nodule.31–33 As a result, we can adopt a more conservative
approach to certain nodules by employing CT surveillance,
reserving the more invasive procedures for higher risk nodules.
In 2005, in response to the growing problem of small
CT-detected nodules, the Fleischner Society published a man-
agement algorithm.34 The strategy adopted was a conservative
one that mandated that all small nodules should be followed-up
in high-risk people (essentially smokers or former smokers).
More recent guidelines, published by the American College of
Chest Physicians (ACCP),35 generally mirror the Fleischner
guidelines with little change to follow-up recommendations
(table 1). The Fleischner Society have recently responded to the
problem of the subsolid nodule by publishing a further state-
ment on their management.36 For those who are at high risk as
per the US Preventative Services Task Force (USPSTF) criteria,
the Lung CT Screening Reporting and Data System
(Lung-RADS) has been speciﬁcally created.37 However, there is
emerging evidence that implementation of the ACCP guidelines
in the US has been suboptimal and that performance of
Lung-RADS may not be as accurate as an approach using the
Brock University nodule risk prediction model.38 Tables 1–3
show the comparison between these various nodule manage-
ment strategies, which vary considerably.
The British Thoracic Society (BTS) published new guidelines
on the investigation and management of pulmonary nodules in
July 2015 following a comprehensive review of the evidence,
with a third of the references cited from 2012 or later.39
Importantly, recommendations differ substantially from the
earlier guidelines, especially for very small nodules, and recom-
mend higher nodule follow-up thresholds, the use of risk pre-
diction calculators and automated volumetric assessment to
clarify follow-up requirements and growth rates (table 4). The
inclusion of volumetric measurement will be challenging to
implement across the UK but this will be offset by a substantial
reduction in follow-up scans compared with previous guidelines.
The Brock University risk prediction tool, which was developed
from the Pan-Canadian screening cohort32 and the Herder
model, where PET-CT results are available, are recommended to
more accurately deﬁne risk of malignancy. The role of further
imaging, minimally invasive investigations and therapy is
reviewed and recommendations made. This guideline also
includes a service delivery model.
CURRENT CT SCREENING ACTIVITY INSIDE AND OUTSIDE
THE UK
Lung cancer screening by CXR was advocated by the American
Cancer Society in the 1970s, however this recommendation was
withdrawn following evidence from the trials in the 1980s.
Following the publication of the NLST results, the USPSTF
recommended screening with LDCT of individuals aged 55–80
who have accrued at least a 30 pack-year smoking history and
are current or former smokers who have given up for ≤15 years.
The ACCP/American Thoracic Society, American College of
Radiology (ACR) and National Comprehensive Cancer Network
have all also released statements or guidelines for screening.40–42
In February 2015, the US insurers, the Center for Medicare
and Medicaid Services agreed to fund screening of asymptomatic
insured individuals aged 55–77 who meet the USPSTF smoking
criteria.43 The newly instated ‘Obamacare’ enables some 30% of
the uninsured population to access LDCT screening; however,
once a nodule is detected it is classiﬁed as surveillance rather
than screening, and perversely funds are insufﬁcient to cover this
crucial aspect of the screening process. Furthermore, a signiﬁcant
proportion of the US population do not qualify for screening at
all through lack of insurance coverage. What is really required,
therefore, is a national screening programme that is accessible to
individuals from all communities such as the US National Breast
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and Cervical Cancer Early Detection Program.44 Nonetheless,
LDCT screening for insured individuals is now underway in the
US. The ACR runs an accreditation programme outlining basic
standards for performing and evaluating screening scans using
the above-mentioned Lung-RADS.42 At the time of writing, there
were 1220 accredited centres for LDCT screening in the US, 43
of which had been awarded ‘diagnostic imaging centre of excel-
lence’. The ACR has constructed a lung cancer screening registry,
to record outcomes from screening and the ﬁrst feedback was
expected in autumn 2015.45
Screening has not yet been initiated in Canada, and the
European Society of Radiology and European Respiratory
Society recommend that screening should be performed in
‘comprehensive, quality-controlled longitudinal programmes’.46
In China, several lung cancer screening programmes have been
initiated, particularly in areas with high lung cancer incidence,
funded by central or local government.47
The UK National Screening Committee (NSC) is due to make
a decision on lung cancer LDCT screening in the UK pending
the results of the pooled European data.48 In the meantime,
several centres around the UK have initiated early diagnosis
campaigns or pilot screening projects and these will contribute
increasing knowledge around the best methods of implementa-
tion in the UK.49
PRESENT BARRIERS TO SUCCESSFUL IMPLEMENTATION OF
LDCT SCREENING
With these advances in CT technology and pulmonary nodule
management, are we now in a position to recommend screen-
ing? In 1968, Wilson and Jungner compiled a report commis-
sioned by the WHO highlighting that while the concept of
screening was admirable, it was not without difﬁculties in terms
of optimising beneﬁts and harms.50 In order to aid the appro-
priate selection of conditions for which the beneﬁts of screening
outweighed the harms, they outlined 10 screening principles for
appraising the viability, effectiveness and appropriateness of a
screening programme,51 which form the basis for the criteria
outlined by the UK NSC. Table 5 lists these 10 principles, and
Table 1 Comparison of Fleischner, Lung-RADS and ACCP guideline management of SN detected within or outside of screening
Fleischner ACCP Lung-RADS
Low risk High risk Low risk High risk
Baseline scan
No nodules or
nodules with benign
features No follow-up
No follow-up Not specified Category 1 (negative): return to
annual screening at 12 months
<4 mm Interval CT at
12 months
Optional follow-up Interval CT at 12 months
then discharge if stable
Category 2 (benign): return to
annual screening at 12 months
4–6 mm Interval CT at
12 months
Interval CT at 6–12
and 18–24 months
Interval CT at 12 months
then discharge if stable
Interval CT at 6–12 and
18–24 months and discharge
at 24 months if stable
6–8 mm Interval CT at 6–12
and 18–24 months
3–6, 9–12 and
24 months
Interval CT at 6–12 and
18–24 months and
discharge at 24 months if
stable
Interval CT at 3–6, 9–12 and
24 months and discharge at
24 months if stable
Category 3 (probably benign):
interval CT at 6 months
8–15 mm
Interval CT at 3, 9, 24 months, dynamic CT
chest, PET-CT±histology
Risk<5%: perform CT surveillance at 3–6, 9–12 and
18–24 months
If non-FDG avid/ non-enhancing on contrast CT and risk
<40% or negative biopsy: perform CT surveillance at 3–6,
9–12 and 18–24 months
Risk 5%–65%: perform PET and consider biopsy/resection
Risk >65%: PET not required favour histological
confirmation, with surgical resection
Category 4A (suspicious):
PET-CT: interval CT at 3 months
>15 mm
Category 4B (suspicious):
perform standard CT with or
without contrast; PET-CT;
histology
Interval scan
<4 mm (new) Discharge if resolved or at 12 months if no
growth If there is clear evidence of growth (VDT<400 days is
suggestive of malignancy), favour surgical resection
If no growth or decrease in size, follow-up for 2 years or
until nodule disappears
Category 2 (benign): return to
annual screening at 12 months
4–6 mm (new) Discharge if resolved
or at 1 year if no
growth
Discharge if resolved
or at 18–24 months if
no growth
Category 3 (probably benign):
interval CT at 6 months
<8 mm (new/growing) Discharge if resolved
or at 24 months if no
growth
Discharge if resolved
or at 24 months if no
growth
Category 4A (suspicious):
interval CT at 3 months
>8 mm (new/growing) Perform PET-CT±histology
Discharge if resolved or at 24 months if no
growth
Category 4B (suspicious):
perform standard CT with or
without contrast; PET-CT;
histology
N.B. Lung-RADS is for CT screening scans only.
ACCP, American College of Chest Physicians; PET, positron emission tomography; RADS, Reporting and Data System; SN, solid nodules.
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Table 2 Comparison of Fleischner, Lung-RADS and ACCP guideline management of PSN detected at baseline screening or incidental scans
Fleischner ACCP Lung-RADS
Baseline scan
No nodules or
nodules with benign
features
Interval CT at 3 months
If <8 mm: interval CT at 3 and
12 months and then annually for
3–5 years
If multiple, consider each nodule
separately
Category 1 (negative): interval CT at 12 months
<6 mm Category 2 (benign): interval CT at 12 months
≥6 mm with solid
component <6 mm
Category 3 (probably benign): interval CT at 6 months
≥6 mm with solid
component 6–8 mm
Category 4A (suspicious): interval CT at 3 months; PET-CT if
solid component >8 mm
≥6 mm with solid
component ≥8 mm
Interval CT at 3 months+PET if solid
component >8 mm
N.B. If >15 mm, consider PET+biopsy/
resection at baseline
Category 4B (suspicious): standard CT with or without
contrast; PET-CT if solid component ≥8 mm; histology
Interval scan
<6 mm nodule Persistent nodules with solid
component <5 mm: perform annual
CT for minimum 3 years
Annual CT for 3–5 years. Any growth or
development of solid component should
prompt further investigation/resection
<6 mm nodule: category 2 (benign): interval CT at 12 months
≥6 mm with smaller
solid component
≥6 mm nodule solid component <6 mm (or new nodule
<6 mm on interval CT): category 3 (probably benign):
interval CT at 6 months
≥6 mm with larger
solid component
For persistent solitary nodule or
multiple nodules with one dominant
nodule with solid component
>5 mm: favour biopsy/resection
(PET-CT if nodule >10 mm)
Perform PET-CT+biopsy/resection
≥6 mm nodule with solid component 6–8 mm (or new or
growing solid component <4 mm): category 4A (suspicious):
interval CT at 3 months
≥6 mm with solid component >8 mm or new or growing solid
component >4 mm: category 4B (suspicious): standard CT with
or without contrast; PET-CT; histology depending on Brock risk
N.B. Lung-RADS is for CT screening scans only.
ACCP, American College of Chest Physicians; PET, positron emission tomography; PSN, part-solid nodules; RADS, Reporting and Data System.
Table 3 Comparison of Fleischner, Lung-RADS and ACCP guideline management of pGGN detected at baseline screening or incidental scans
Fleischner ACCP Lung-RADS
Baseline scan
<5 mm No follow-up if solitary, but if multiple, perform interval
CT at 2 and 4 years
No follow-up See below
>5 mm Interval CT at 3 months, then annual for minimum 3 years
(for solitary and multiple nodules)
Annual CT surveillance for minimum
3 years (follow-up at 3 months if
>10 mm)
<20 mm
As above
Category 2 (benign): interval CT at
12 months
≥20 mm Category 3 (probably benign):
interval CT at 6 months
Interval scan
New nodule
<20 mm
As for baseline scan
If >10 mm and persistent or growing
favour resection
Category 2 (benign): interval CT at
12 months
≥20 mm and stable
or slow growth
Category 3 (probably benign):
interval CT at 6 months
Persistent nodule Annual CT surveillance for a minimum of 3 years
Favour excision if nodule >10 mm or multiple pGGN with
a persistent dominant nodule
Biopsy noted to have low yield
>20 mm and stable or slowly
growing=category 2 (benign):
interval CT at 12 months
N.B. Lung-RADS is for CT screening scans only.
ACCP, American College of Chest Physicians; pGGN, pure ground glass nodules; RADS, Reporting and Data System.
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proposes key factors that need to be addressed for successful
implementation of a lung cancer screening programme. These
factors are discussed below.
Radiation risk
Advances in CT scanning technology have improved nodule
detection and characterisation while reducing radiation dose.
Techniques such as iterative reconstruction (which reduces the
extent of noise and artefact associated with images at lower radi-
ation doses), altering tube voltage, current and gantry rotation
speed are valuable in reducing effective radiation doses. Further
reduction to overall radiation exposure over time will follow
implementation of the more conservative approaches to man-
aging positive ﬁndings, suggested in the more recent guide-
lines.52 Nevertheless, radiation risk will remain a problem and
always needs to be considered when balancing risks and beneﬁts.
Overdiagnosis and false positives
Overdiagnosis is the detection and characterisation of disease
that would not otherwise cause harm. It may be minimised in
LDCT screening by taking into account morphological features
that denote more indolent cancers that may be managed with a
more conservative approach less likely to cause harm. False posi-
tives are benign lesions that undergo investigation and may
therefore result in harm, both physical and psychological. Pure
ground glass nodules53 and solid and subsolid nodules with
longer volume doubling times are more likely to be indolent30
or benign. The recent BTS guidelines support a more conserva-
tive management of volumetrically assessed, potentially indolent
or benign lesions, thus reducing the rate of overdiagnosis and
benign histological diagnoses.
Optimal eligibility criteria for screening
It is clear that overdiagnosis rates, false positive rates, the
number needed to be screened to save one life from lung cancer
and cost of screening can all be reduced by selecting the higher
risk population.54 However, what the appropriate threshold for
risk is, and how this interacts with entry and exit age, compet-
ing mortality and ﬁtness are complex. Randomised trials of
LDCT screening have adopted a number of different approaches
in determining who to invite to screening. The UKLS sent out
questionnaires which enabled determination of the Liverpool
Lung Project lung cancer risk prediction algorithm and had a
relatively high lung cancer detection rate (2.1%),55 while the
NLST used just age and smoking status. Which risk assessment
tool most appropriately balances simplicity and predictive accur-
acy still needs to be determined. Furthermore, based on the
results from the NELSON study, screening interval may also
need to be varied by risk. They showed that interval cancers
occur at a low rate (1%) and this occurrence was associated with
age but not smoking status.56 Further research into other factors
predictive of interval cancers is needed. With ongoing research
into potential biomarkers, LDCT screening may one day be
offered to a wider demographic and include non-smokers with a
positive biomarker test.
Balance of psychological impact
The psychological burden of screening remains to be determined,
and for the individual, may in large part depend on the severity
Table 4 Summary of BTS guidelines for management of pulmonary nodules detected at baseline screening or incidental scans
Solid nodules Part solid nodules
Pure ground
glass nodules
Baseline scan
<5 mm or <80 mm3 Discharge Discharge
5–6 mm CT at 12 months
Interval CT at 3 months
≥6 to <8 mm or 80 to
<300 mm3
Interval CT at 3 and 12 months
>8 mm or >300 mm3 1. PET-CT
2. Assess Herder risk
▸ If <10%: do CT at 3 and 12 months
▸ If >10%: consider biopsy or resection or CT
surveillance on individual basis
▸ If >70% favour resection
Interval scan
2D
Stable nodule Discharge after 2 years
If stable or smaller, assess Brock risk at 3 months
▸ If risk <10%, continue CT surveillance at 1, 2 and 4 years (or
until nodule disappears)
▸ If risk >10% or concerning morphology, consider histological
diagnosis and discuss options with patient
▸ If growth or altered morphology (especially if growth of solid
component by ≥2 mm) favour further work up and definitive
management
N.B. Consider PET if solid component ≥8 mm
Growing PET-CT and Herder score
3D
Stable or slow growth Discharge if stable, and discharge or ongoing
surveillance if slow growth (VDT>600 days)
VDT 400–600 days Further surveillance or biopsy or resection are
acceptable, and decision should be based on patient
preference
VDT ≤400 days Further work up, and consider definitive management
BTS, British Thoracic Society; PET, positron emission tomography; 2D, two-dimensional; 3D, three-dimensional.
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of the screening result and psychosocial characteristics. To date,
most studies of trial participants undergoing lung screening have
shown that the anxiety and distress associated with false positive
screens are minimal and short-lived.57 Clinically, meaningful
changes in health-related quality of life were observed one month
after the detection of an indeterminate pulmonary nodule, but
returned to prescreening levels after two years, suggesting no
long-lasting effects.58 59 However, this is yet to be studied in the
community context and there is evidence from other screening
programmes for long-term psychological distress.60 Furthermore,
given a signiﬁcant proportion of screening participants will at
one time receive a false positive or indeterminate result, further
research is needed to monitor the psychological impact of the
surveillance process, examine individual differences in response
and develop strategies which minimise harm. Qualitative evi-
dence suggests effective communication about indeterminate
nodules by health professionals could be one such strategy,61 and
ensuring patients are well-informed about the screening process
and possible results will be essential. In addition, there is concern
that an ‘all clear result’ could be falsely interpreted to mean low
future risk of developing lung cancer, and a lower susceptibility
to the effects of smoking. This issue of over-reassurance has been
studied for other cancer types, with evidence that it may com-
promise future symptom appraisal and delay symptomatic help-
seeking.62 Care must therefore be taken to tailor individual com-
munication, so as to minimise adverse psychological responses to
screening and any negative impact on future health behaviours.
Incidental ﬁndings from screening
Incidental ﬁndings are often viewed as a negative aspect of CT
screening, but their detection may also provide an opportunity
to rectify other conditions that threaten quality of life or sur-
vival. The NLST reported a 6.7% reduction in all-cause mortal-
ity, an effect most pronounced in Black African–Americans.15 63
This may be explained by detection of clinical and radiological
ﬁndings in the process of screening, and due to the improved
access to healthcare brought about by screening that may
prompt intervention for non-lung cancer co-morbidities.64
Several studies have shown that ungated LDCT scans can accur-
ately predict coronary calcium and subsequent cardiovascular
events comparable to formal coronary calcium scoring.65 66
Those at high risk of lung cancer are also at higher risk of car-
diovascular disease, and combining risk assessment and screen-
ing provides opportunity to improve outcomes for both
conditions. However, further prospective studies are needed.
LDCT scans have also been shown to be useful for detecting
emphysema,67 which is a recognised risk factor for lung cancer,
and osteoporosis which was associated with all-cause mortality
in the NELSON cohort.68
Co-implementation of smoking cessation
Achieving smoking abstinence in combination with LDCT
screening has been reported to almost double the reduction in
lung cancer mortality compared with screening alone within the
NLST participants,63 but the impact of screening on smoking
cessation is unclear. Several studies have reported increased
smoking cessation in trial participants compared with the back-
ground population. However, no signiﬁcant differences in out-
comes between the screened and control groups have been
noted, suggesting that trial participants may be a more motivated
group.69–75 Few studies have noted an increase in the number of
participants abstaining from smoking with successive positive or
indeterminate screen results compared with those with negative
screens.76–78 The optimal method of promoting smoking cessa-
tion in screening participants has not been determined. Further
studies of patients, rather than trial participants, in the real-life
screening context are needed to further explore this.
Resource implications and availability of volumetric
assessment
Several studies, based primarily on US data, have reported
varying Incremental Cost Effectiveness Ratios per quality of life
Table 5 Current issues to be addressed for implementation to lung cancer LDCT screening in the UK with reference to Wilson and Jungner50
criteria
WHO Wilson and Jungner50 criteria Met Key factors for implementation
1. The condition sought should be an important health problem Yes
2. There should be an accepted treatment for patients with recognised disease Yes
3. Facilities for diagnosis and treatment should be available Resource implications and availability of volumetric assessment
4. There should be a recognisable latent or early symptomatic stage Yes Overdiagnosis and false positive rates
5. There should be a suitable test or examination Yes Radiation risk
6. The test should be acceptable to the population Yes Balance of psychological impact
Equitable access, uptake and adherence to screening across the
population
7. The natural history of the condition, including development from latent to declared disease,
should be adequately understood
Yes
8. There should be an agreed policy on whom to treat as patients Optimal eligibility criteria for screening
9. The cost of case finding (including diagnosis and treatment of patients diagnosed) should be
economically balanced in relation to possible expenditure on medical care as a whole
Yes Co-implementation of smoking cessation
Incidental findings from screening
10. Case-finding should be a continuing process and not a ‘once and for all’ project Interval cancer rate
Regulating CT screening
LDCT, low dose CT.
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adjusted life year (QALY) gained, ranging from US$28 000 to
over US$100 000.79–81 The cost of lung cancer screening in the
UK is not known, but has been estimated to be around £9000
per QALY gained;55 well below the threshold of £30 000
deemed acceptable by the National Institute for Health and
Care Excellence. If NLST eligibility criteria were to be imple-
mented, an estimated 8.7 million people in the US may be eli-
gible for screening.82 The size of the UK lung cancer screening
eligible population is unclear, however, even assuming uptake
levels may be low (in the region of 50%), numbers are likely to
be signiﬁcant. This has considerable resource implications in
terms of carrying out the baseline and interval CT scans
required for nodule follow-up.
Most hospitals now have the technology to perform LDCT
scans and take advantage of many of the other CT advances
such as Maximum Intensity Projections (which allow enhanced
visualisation of high attenuating structures such as nodules) and
Multi-Planar Reconstruction (where images are reconstructed in
customised planes). Automated estimation of the volume of
nodules, calculated by mapping the CT attenuation values, is
also possible with modern volumetric nodule assessment
packages. These packages also autocalculate volume doubling
times, which can more accurately quantify growth of a nodule
than conventional two-dimensional measurements.83 However,
exactly what proportion of UK hospitals currently has access to
the technical, radiological and clinical know-how to implement
volumetric assessment needs to be determined.
Various strategies as outlined above including appropriate
selection criteria for screening and improved management of
pulmonary nodules will help reduce the cost of screening. The
cost of various methodologies that can be used in the screening
process, such as the use of mobile CT scanners versus dedicated
screening centres, also needs to be evaluated. Scan reading time
is also a factor, and research is needed to explore whether there
are feasible options that will relieve some of the work from
radiologists.
Equitable access, uptake and adherence to screening across
the population
Participation in national screening programmes for breast and
colorectal cancer is around 70% and 60%, respectively,84–87 but
there is evidence to suggest this will be lower in future lung
cancer screening programmes. In the NELSON trial, 32% of
the approached persons (aged 50–75 years) in the general popu-
lation responded to an initial questionnaire on general health,
lifestyle and smoking history (which did not mention the
NELSON trial88), similar to the response rate for the UKLS
pilot randomised control trial.89 In NELSON, 19% (6%
overall) of these were at high risk and half gave informed
consent and were recruited. In UKLS, only 11.5% met the risk
threshold for trial entry (higher than for NELSON) and a
similar proportion were recruited. Although participation in a
trial might be less than in a screening programme, in both of
these well-conducted studies the participation rate of higher risk
people was low enough to be of concern for implementation.
UKLS also showed that current smoking and low socio-
economic status (SES) were associated with lower uptake, a
problem observed across European and US trials90 91 and for
other cancer screening programmes more widely.92 Lung cancer
prevalence is higher in lower SES communities, where lifelong
smokers are both over-represented93 and more tobacco-
dependent.94 Indeed, over 40% of the lung cancers detected in
UKLS were in people from the most deprived quintile.
Reported barriers to participation among smokers include
concern about risk of lung cancer, a lower perceived beneﬁt of
early detection, perceived blame and stigma and fearful, fatalis-
tic and nihilistic beliefs around lung cancer outcomes.95–97 In
addition, methods of recruitment, which demand signiﬁcant
correspondence from potential participants (as required by most
trials), are likely to increase attrition among lower SES groups.
A UK study has begun recruitment to a trial examining a tai-
lored invitation method designed to overcome these barriers
and reduce inequalities in participation (Quaife et al, manuscript
in preparation).
Factors affecting screening adherence may be similar to those
affecting uptake, with the added complexity of psychological
responses to positive and negative results received in previous
screening rounds.98 Given that the ratio of screening beneﬁt to
risk increases with lung cancer risk, promoting engagement of
the higher risk and hard-to-reach groups aims to reduce lung
cancer inequalities and improve the cost-effectiveness and efﬁ-
cacy of screening.
Regulating CT screening
Any screening programme needs to have stringent audit and
quality control to ensure compliance with best practice.
Availability of adequate resources to successfully implement and
deliver such a programme to a high standard is vital. Controls
also need to be in place to ensure uniformly low radiation doses
are used, scans are read to an adequate level of accuracy and
that nodules and other ﬁndings are appropriately managed. A
database to record outcomes is crucial to enable measurement
of screening outcomes and further develop and improve the
protocols used for all aspects of screening.
CONCLUSION
LDCT screening is undoubtedly a promising method to improve
lung cancer outcomes. If lung cancer screening is to be initiated
in the UK, adequate provision of resources is essential, with
employment of stringent screening protocols and regulatory
processes to ensure beneﬁts outweigh harms and costs are mini-
mised. Although it is acknowledged that the UK NHS is under
considerable resource pressure, lung cancer is a condition that
has not seen the improved outcomes observed in other cancers.
With an overall 5-year survival for lung cancer in the UK
<13%2 and the limited efﬁcacy of available treatments for late-
stage disease, there seems to be no alternative but to proceed
with screening to improve rates of early detection and curative
treatment.
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